AUTHOR=Qiu Jian-Ge , Wang Lin , Liu Wen-Jing , Wang Ju-Feng , Zhao Er-Jiang , Zhou Feng-Mei , Ji Xiang-Bo , Wang Li-Hong , Xia Zhong-Kun , Wang Wei , Lin Marie Chia-mi , Liu Ling-Zhi , Huang Ying-Xue , Jiang Bing-Hua 

TITLE=Apigenin Inhibits IL-6 Transcription and Suppresses Esophageal Carcinogenesis

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 10 - 2019

YEAR=2019

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01002

DOI=10.3389/fphar.2019.01002

ISSN=1663-9812

ABSTRACT=Esophagus cancer is the seventh causes of cancer-related deaths globally. In this study, we analyzed IL-6 gene expression in human esophagus cancer patients, and showed that IL-6 mRNA levels are significantly higher in tumor tissues and negatively correlated with overall survival, suggesting that IL-6 is a potential therapeutic target for esophagus cancer. We further demonstrated that apigenin, a nature flavone product of green plants, inhibited IL-6 transcription and gene expression in human esophagus cancer Eca-109 and Kyse-30 cells. Apigenin significantly and dose-dependently inhibited cell proliferation, and promoted apoptosis while stimulating the cleaved PARP (C-PARP) and Caspase-8 expression. It suppressed VEGF expression, and tumor-induced angiogenesis. Pretreatment of cells with IL-6 could completely reverse apigenin induced cellular changes. Finally, using a preclinical nude mice model subcutaneously xenografted with Eca-109 cells, we demonstrated the in vivo anti-tumor activity and mechanisms of apigenin. Taken together, this study revealed for the first time that apigenin is a new IL-6 transcription inhibitor, and that inhibiting IL-6 transcription is one of the mechanisms by which apigenin exhibits its anti-cancer effects. The potential clinical applications of apigenin in treating esophagus cancer warrant further investigations.